The immune system exists to protect the body from pathogens and abnormal cells. In autoimmune diseases, this same system malfunctions, producing antibodies or cytotoxic immune cells that attack the body's own healthy tissues. More than 80 distinct autoimmune diseases have been identified, collectively affecting approximately 50 million Americans — roughly 15% of the population. They are, as a group, more common than heart disease and cancer in women, yet research funding and public awareness remain comparatively limited.
Common Autoimmune Diseases
While each autoimmune condition targets different tissues, the underlying mechanism — loss of immune tolerance to self-antigens — is shared. Rheumatoid arthritis (RA) attacks joint synovium, causing progressive inflammatory joint destruction. Systemic lupus erythematosus (SLE) can affect skin, kidneys, heart, lungs, joints, and the nervous system. Multiple sclerosis (MS) targets the myelin sheath of central nervous system neurons, disrupting signal conduction. Type 1 diabetes mellitus destroys pancreatic beta cells. Hashimoto's thyroiditis and Graves' disease target the thyroid. Inflammatory bowel disease (Crohn's disease, ulcerative colitis) attacks the gastrointestinal tract. Psoriasis drives overproduction of skin cells. A hallmark across many autoimmune diseases is a relapsing-remitting course — periods of flare alternating with partial or complete remission.
Diagnosis Challenges
Autoimmune diseases are notoriously difficult to diagnose. Many overlap in their presentations, sharing nonspecific symptoms — fatigue, joint pain, rash, and fever — that mimic other conditions. The average diagnostic delay across autoimmune diseases is 3–5 years. Diagnosis relies on a combination of symptom pattern, physical examination, autoantibody testing (ANA, anti-dsDNA, RF, anti-CCP, ANCA, and many others), organ-specific biomarkers, and imaging or biopsy findings. No single test confirms most autoimmune diagnoses; clinical integration is essential.
Treatment Approaches
Treatment has been transformed by the development of biologic therapies targeting specific inflammatory pathways. TNF-alpha inhibitors (adalimumab, etanercept, infliximab) are effective across RA, psoriasis, IBD, and ankylosing spondylitis. IL-17, IL-23, and IL-6 inhibitors target more specific inflammatory pathways. JAK inhibitors offer oral alternatives with broad anti-inflammatory efficacy. Conventional disease-modifying drugs (methotrexate, hydroxychloroquine, azathioprine) remain important, particularly in lower-resource settings. Treatment goals have shifted from symptom control to disease remission — suppression of clinical and radiological disease activity — which meaningfully reduces long-term organ damage and disability.
Frequently Asked Questions
Why are autoimmune diseases more common in women?
Approximately 80% of autoimmune disease patients are women. Oestrogen modulates immune function in ways that enhance antibody production and inflammatory responses, while testosterone appears to have some immunosuppressive effect. Hormonal fluctuations across the menstrual cycle, pregnancy, and menopause frequently influence disease activity. Genetic factors on the X chromosome — particularly genes regulating immune tolerance — may also contribute.
Do autoimmune diseases run in families?
Yes, but not in a simple predictable pattern. Family members of people with one autoimmune disease have elevated risk of developing autoimmune disease — not necessarily the same one. This suggests shared genetic susceptibility (particularly HLA gene variants) that can express differently across family members depending on environmental exposures and triggers.
Sources
- AARDA. Autoimmune Disease Statistics. 2023.
- Rosenblum MD, et al. Mechanisms of Human Autoimmunity. J Clin Invest. 2015.
- Mayo Clinic. Autoimmune disease. 2023.